Advancements in gene sequencing, editing, and bioinformatics have provided an unparalleled understanding of the genetic basis of human physiology and disease. However, the majority of proteins and pathways remain under-characterized and lack chemical probes, posing significant challenges for drug discovery. To address these gaps, our laboratory focuses on developing new chemical modalities, chemical probes, and activity-based protein profiling (ABPP) platforms to pioneer new therapies.